Olanzapine enhances the response of PD-(L)1 inhibitor immunotherapy: A retrospective efficacy analysis in advanced malignancies.
코호트
2/5 보강
PICO 자동 추출 (휴리스틱, conf 3/4)
유사 논문P · Population 대상 환자/모집단
1933 patients with advanced cancer receiving PD-(L)1 inhibitors + chemotherapy (2018-2022), 99 received concurrent olanzapine for chemotherapy-induced nausea.
I · Intervention 중재 / 시술
concurrent olanzapine for chemotherapy-induced nausea
C · Comparison 대조 / 비교
추출되지 않음
O · Outcome 결과 / 결론
Multivariate analysis confirmed olanzapine correlated with prolonged OS (HR = 0.510, 95% CI:0.282-0.917, = 0.026). Olanzapine may enhance survival benefits in patients with advanced cancer undergoing PD-(L)1 inhibitor therapy.
OpenAlex 토픽 ·
Cancer Immunotherapy and Biomarkers
Tryptophan and brain disorders
Cancer, Stress, Anesthesia, and Immune Response
This retrospective cohort study explores olanzapine's immunomodulatory role and clinical impact in patients with advanced cancer on PD-(L)1 inhibitors, given that chronic stress may impair immune chec
- 95% CI 0.282-0.917
- HR 0.510
- 연구 설계 cohort study
APA
Yanling Yi, Meng-xue Mei, et al. (2026). Olanzapine enhances the response of PD-(L)1 inhibitor immunotherapy: A retrospective efficacy analysis in advanced malignancies.. iScience, 29(5), 115568. https://doi.org/10.1016/j.isci.2026.115568
MLA
Yanling Yi, et al.. "Olanzapine enhances the response of PD-(L)1 inhibitor immunotherapy: A retrospective efficacy analysis in advanced malignancies.." iScience, vol. 29, no. 5, 2026, pp. 115568.
PMID
42028022 ↗
Abstract 한글 요약
This retrospective cohort study explores olanzapine's immunomodulatory role and clinical impact in patients with advanced cancer on PD-(L)1 inhibitors, given that chronic stress may impair immune checkpoint inhibitor (ICI) efficacy. Among 1933 patients with advanced cancer receiving PD-(L)1 inhibitors + chemotherapy (2018-2022), 99 received concurrent olanzapine for chemotherapy-induced nausea. After excluding 58 cases, 41 olanzapine-treated patients were propensity score-matched (PSM) for age, gender, and cancer type. Survival outcomes were analyzed via Kaplan-Meier curves and log rank tests. The olanzapine cohort showed higher objective response rate (ORR) (39.02% vs. 26.83%), comparable median PFS (9 vs. 6 months, = 0.057), and significantly longer median OS (28 vs. 9 months, = 0.019). Multivariate analysis confirmed olanzapine correlated with prolonged OS (HR = 0.510, 95% CI:0.282-0.917, = 0.026). Olanzapine may enhance survival benefits in patients with advanced cancer undergoing PD-(L)1 inhibitor therapy.
🏷️ 키워드 / MeSH 📖 같은 키워드 OA만
🏷️ 같은 키워드 · 무료전문 — 이 논문 MeSH/keyword 기반
- Creative Arts Therapy for Anxiety, Depression, and Quality of Life in Cancer Patients: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
- Building Hybrid Pharmacometric-Machine Learning Models in Oncology Drug Development: Current State and Recommendations.
- Elevated Plasma IL-18 Levels During Chemotherapy Treatment for Breast Cancer, Exercise Capacity, and Physical Activity.
- Integrative Computational Approaches to Prostate Cancer with Conditional Reprogramming and AI-Driven Precision Medicine.
- AllergoOncology in Review: Harnessing Allergy in the Field of Oncology to Improve Patient Outcomes.
- Three Strategic Pillars for Implementing Endoscopic Nipple-Sparing Mastectomy.